Lin Wei
Known title: Chief Medical OfficerCIK: 0001872772
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Erasca Faces Verastem Competition Amid Clinical Updates. Recent analysis highlights that Verastem's upcoming clinical data and commercial launch present a competitive challenge for Erasca. While Erasca's Revolution approval has reduced some development risk, the market is watching how the company navigates this new competitive landscape. The stock currently trades near significant support levels, reflecting cautious sentiment as investors assess these developments.
Transaction History
| RVMD | ▼ Sell | Open Market | 2,073 | $206K | 3/17/2026 | View on chart |
| RVMD | ▲ Buy | Grant | 15,100 | $0 | 3/1/2026 | View on chart |
| RVMD | ▼ Sell | Open Market | 2,160 | $99K | 9/16/2025 | View on chart |
| RVMD | ▼ Sell | Open Market | 2,173 | $87K | 6/16/2025 | View on chart |
| RVMD | ▲ Buy | Grant | 20,800 | $0 | 3/1/2025 | View on chart |
| RVMD | ▼ Sell | Open Market | 5,589 | $209K | 6/17/2024 | View on chart |
| ERAS | ▼ Sell | Other | 1,748 | $7K | 2/1/2023 | View on chart |
| ERAS | ▼ Sell | Other | 2 | $8 | 2/1/2023 | View on chart |
| ERAS | ▼ Sell | Other | 1,562 | $18K | 2/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
RVMD RASONQUE Receives Positive EU CHMP Opinion
The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for Revolution Medicines’ RASONQUE (daraxonrasib) in metastatic pancreatic cancer. This development supports the company’s pipeline and may broaden its commercial prospects in Europe. Analysts have maintained their target price, reflecting confidence in the drug’s potential.
RVMD RASONQUE Receives Positive EU CHMP Opinion. The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for Revolution Medicines’ RASONQUE (daraxonrasib) in metastatic pancreatic cancer. This development supports the company’s pipeline and may broaden its commercial prospects in Europe. Analysts have maintained their target price, reflecting confidence in the drug’s potential.